We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs, Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Books » The MDSAP in 2022: Policies, Procedures and Developments

Other Options

PDF Edition

$297.00

PDF Edition – 3-4 Copies (10% Off)

$267.00

PDF Edition – 5-6 Copies (15% Off)

$252.00

PDF Edition – 7-9 Copies (20% Off)

$237.00

PDF Edition – 10+ (25% Off)

$223.00
The MDSAP in 2022: Policies, Procedures and Developments

The MDSAP in 2022: Policies, Procedures and Developments

$297.00
Books

Product Details

For devicemakers hoping to enter the global market, the Medical Device Single Audit Program (MDSAP) is a must.

MDSAP success can get your devices to market faster and it precludes being subject to routine FDA inspections, leading to a much less stressful relationship with the FDA.

The MDSAP in 2022: Policies, Procedures and Developments has everything you must know about the workings of MDSAP audits, new developments and strategies for success.

In the past three years alone, a multitude of procedures have been refined and Argentina, the Republic of Korea and Singapore have joined the U.S., Australia, Canada, Japan and Brazil — with more on the way. The MDSAP in 2022 provides a comprehensive view of the current state of MDSAP, enabling you to reap the vast potential of the program.

This report details the program’s principles and procedures, policy developments in individual countries, guidance from the FDA and more. It has the up-to-date intelligence you need to help you make the most of your resources and come through your audits with top marks.

The MDSAP in 2022 shows you the specifics of how MDSAP audits work, including details about frequency, duration and areas of scrutiny. It explains how to prepare for them by taking advantage of resources that guide the auditors themselves. And it pinpoints which regulators require them, which may be about to make them mandatory and the benefits of voluntary participation.

Management report takeaways: 

  • What has changed in the past three years: which countries are participating in MDSAP and which of those require an MDSAP audit
  • How MDSAP audits can be conducted remotely
  • The different types of audits involved, such as initial certification, surveillance, desk and onsite audits
  • The standard schedule for and duration of audits
  • Specific areas auditors will examine and questions they will ask
  • How to use the MDSAP companion document to create an audit preparation checklist that matches the auditors’ process
  • The MDSAP grading system and how nonconformance issues can be escalated — and the consequences of getting a bad grade
  • Costs of an MDSAP audit

 

Bonus: Includes copies of the MDSAP manual and its companion document for step-by-step instructions, guidance from the FDA on remote MDSAP audits, a guide to the program’s nonconformity grading scale and other valuable resources.

You can save time, effort and money by using MDSAP. Maximize your success with The MDSAP in 2022: Policies, Procedures and Developments.  


About the Contributor

Connie Hoy is a former EVP of regulatory, quality and clinical development at Cynosure, a division of Hologic, with three decades of experience in the medical device industry. Since leaving Cynosure in 2018, Ms. Hoy has led a number of companies through the process of obtaining MDSAP certification. She also performs internal audits that meet the requirements of MDSAP.

 

Who Will Benefit

  • Regulatory/compliance staff
  • Quality managers
  • Senior executives

PDF

$297.00
Add to Cart

Contributor:
Connie Hoy

ISBN-13:
978-1-60430-184-7

Publication date:
Jan. 2022

Page count:
493


Multi-user Access
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Books Library — a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.


Our Guarantee
Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing